Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Sees Large Decline in Short Interest

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) was the recipient of a large decline in short interest during the month of June. As of June 15th, there was short interest totaling 137 shares, a decline of 55.8% from the May 31st total of 310 shares. Based on an average daily volume of 3,304 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company’s shares are short sold.

Enzon Pharmaceuticals Trading Down 4.8%

Shares of OTCMKTS ENZN traded down $0.24 during midday trading on Wednesday, hitting $4.75. The stock had a trading volume of 709 shares, compared to its average volume of 1,344. The company’s 50-day simple moving average is $5.80 and its 200 day simple moving average is $5.71. The firm has a market cap of $3.52 million, a P/E ratio of -0.69 and a beta of -0.06. Enzon Pharmaceuticals has a fifty-two week low of $1.50 and a fifty-two week high of $11.70. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.01 and a quick ratio of 1.16.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last issued its quarterly earnings results on Monday, May 4th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter. The firm had revenue of $86.54 million during the quarter.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.